Bayer Pharma Aktiengesellschaft

Siemens Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Gregor Jost

Hubertus Pietsch

Thomas Frenzel

Jessica Lohrke

Markus Berger

Christoph-Stephan Hilger

Olaf Panknin

Johannes Platzek

Detlev Suelzle

Thomas Flohr

Wolfgang Ebert

Bernhard Schmidt

Detlev Sülzle

Thomas Brumby

Michael Grasruck

Sven Wittrock

Wolfgang Halfbrodt

Simon Anthony Herbert

Stephan Holzschuh

Martin Rohrer

Gesine Knobloch

Claus-Peter Reisinger

Rüdiger Lawaczeck

Gunnar Schütz

Ivo Matteo Baltruschat

Harald Kramer

Thomas Fenzel

Matthias Lenga

Claudia Green

Felix Karl Kreis

Gunnar SCHÜTZ

Christian Lienerth

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Gadolinium chelate compounds for use in magnetic resonance imaging

The present disclosure relates to a liquid pharmaceutical formulation comprising a DO3A-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gdion, and R, R, R, Rand Rare as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Formulation of contrast media and process of preparation thereof

The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gdion, and R, R, R, Rand Rare as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

Systems, methods, and computer program products for determining different states of a contrast agent in different types of tissue can involve generating a magnetic resonance waveform for the contrast agent in an examination region that includes multiple tissue types. The contrast agent may have different relaxation-shortening effects in each different tissue type. The generated waveform may be compared to database waveforms to determine the concentration of the contrast agent in each tissue type in the examination region.

Magnetic resonance fingerprinting method for recordings with a contrast agent

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.

Determination of a time-dependent contrast agent injection curve as a function of CT scan parameters

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. 

A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation &#x394;W=W&#x2212;Wwherein Wis a first width of the contrast agent bolus profile at a first vessel position and Wis a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.

Method for optimizing the predetermination of the time profile of a contrast agent concentration in diagnostic imaging using a magnetic resonance system

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

A method is disclosed for generating at least one x-ray image of a patient having incorporated contrast medium, using x-rays having an energy spectrum and an x-ray detector. The energy spectrum is modified by at least one first filter arranged in the beam path in front of the patient, the patient absorbing a dose in order to generate detector data for the x-ray image and the x-ray image having a CNR value which represents the ratio of the maximum contrast in the image to the noise. The energy spectrum and contrast medium are matched to each other, taking into account the thickness of the patient to be x-rayed, in such a way that an optimization criterion which is taken from an x-ray image that is generated or simulated by way of trials is maximized. Furthermore, an x-ray system is also disclosed.

Method for generating a contrast medium-assisted X-ray image and X-ray system

A mammography CT system is disclosed which includes an X-ray generator; and a first radiator-detector system. A contrast medium, including an opacifying element including an absorption peak in a first energy range, is useable for tomographic imaging of a female breast of a patient. After filtering, the X-rays with a prespecified tube voltage that form at an anode, are configured to emit an X-ray spectrum having a second energy range, wherein the radiator-detector system is configured to acquire a plurality of circumferential projections around the breast. The first energy range is a part of the second energy range and the second energy range includes an upper limit of less than 70 keV and a lower limit of greater than 20 keV. A corresponding method for generating tomographic mammography CT images is also disclosed.

Combination of contrast medium and mammography CT system with a prespecified energy range and method for generating tomographic mammography CT images by this combination

Growing community of inventors

Berlin, Germany

Gregor Jost